Healthcare Triangle Inc

Healthcare Triangle Inc (HCTI) Stock Analysis

$3.690

+0.103 (+2.79%)At close

Loading chart…
High
3.830
Open
3.710
VWAP
3.72
Volume
10.60K
Mkt Cap
2.90M
Low
3.650
Amount
39.48K
EV/EBITDA, TTM
-0.90

Healthcare Triangle, Inc. is a healthcare information technology company. The Company is focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry. Its Software Services segment provides strategic advisory, implementation, and development services. Its Managed Services and Support segment includes post-implementation support and cloud hosting. Its Customer Engagement Services provide customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. The Company's proprietary platforms include CloudEz, DataEz, Readabl.AI, Ziloy, and Ezovion. Through its platform, solutions, and services, the Company supports healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and life sciences, biotech companies, and medical device manufacturers.

AI analysis of Healthcare Triangle Inc (HCTI)

Sell

HCTI is not a good buy right now due to its extremely low RSI of 15.487, indicating it is oversold, and a staggering year-to-date change of -99.50%, which reflects severe declines in value. The company has also reported consistent net losses, with a net income of -6198000 in Q1 2026 and -4415000 in Q2 2026, which raises concerns about its financial health. The main risk is the potential for further declines in stock price, given its current position at 0.0% of the 52-week range, indicating it is trading at its lowest point.

Valuation Metrics

The current forward P/E ratio for Healthcare Triangle Inc (HCTI) is 0.00, compared to its 5-year average forward P/E of -1.43.

Forward P/E

Fair
5Y Average P/E
-1.43
Current P/E
0.00
Overvalued
1.31
Undervalued
-4.16

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.67
Current EV/EBITDA
-0.90
Overvalued
13.32
Undervalued
-14.66

Forward P/S

Fair
5Y Average P/S
0.32
Current P/S
0.08
Overvalued
0.69
Undervalued
-0.05

Events Timeline

2026-11-02 (ET)

09:30:00

Healthcare Triangle Expands Potential Business in Indonesia to $45M

2026-10-20 (ET)

09:30:00

Healthcare Triangle's Teyame Signs Six Client Engagements, Estimated Annual Revenue of $1.34M

2026-09-30 (ET)

14:30:00

Healthcare Triangle Signs MOU with AI World

2026-09-23 (ET)

09:30:00

Healthcare Triangle Signs LOI to Acquire Roboticom

2026-09-03 (ET)

09:30:00

Healthcare Triangle Signs Separation Agreement with Teyame AI Holdings

News

HCTI FAQ — answered by Alphio AI

Healthcare Triangle, Inc. is a healthcare information technology company. The Company is focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry. Its Software Services segment provides strategic advisory, implementation, and development services. Its Managed Services and Support segment includes post-implementation support and cloud hosting. Its Customer Engagement Services provide customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. The Company's proprietary platforms include CloudEz, DataEz, Readabl.AI, Ziloy, and Ezovion. Through its platform, solutions, and services, the Company supports healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and life sciences, biotech companies, and medical device manufacturers. It operates in the Technology sector (SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN industry).

HCTI is not a good buy right now due to its extremely low RSI of 15.487, indicating it is oversold, and a staggering year-to-date change of -99.50%, which reflects severe declines in value. The company has also reported consistent net losses, with a net income of -6198000 in Q1 2026 and -4415000 in Q2 2026, which raises concerns about its financial health. The main risk is the potential for further declines in stock price, given its current position at 0.0% of the 52-week range, indicating it is trading at its lowest point.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading